View the ALIPRATINIB registration information details.
Back to drug list
ItemsDrug Registration information
ID1613
No1613
Brand NameALIPRATINIB
IngredientsPRALSETINIB 100 MG
Dosage FormCAPSULE
Primary PackagingBOTTLE
Storage
Shelf Life2 YEARS
Pack SizeBOX OF 60 CAPSULES/BOTTLE
Dispensing Category
ATC Classification
Pharmaceutical Class
IndicationsMETASTATIC REAARANGED DURING TRANSFECTION FUSION POSITIVE NON SMALL CELL LUNG CANCER, RET mutant medullary thyroid cancer, RET fusion positive thyroid cancer
Contraindications
Side Effects
Unit Price
EDLNULL
DescriptionLIGHT BLUE CAPSULE CONTAINS WHITE POWDER
Note
License OwnerLAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY
ManufacturerLAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY
CountryLAOS
Import Registration No
Import Registration Date
ActivityCERTIFICATE RELEASED
Applied Date
FDD Registration No05 L 1102/24
FDD Registration Date27/05/2024
Expiry Date26/05/2027
Back to drug list
ADB ASEAN COVID-19 Laos JICA KOICA Global Fund WFP UHS Laos World Bank MOH Laos UNODC WHO SIDA